Under the settlement agreement, the company inked a Deferred Prosecution Agreement (:DPA) with the United States Department of Justice. The duration of the DPA is up to 2 years and 6 months. In a ...

AUSTIN, TX—Arash Nafissi, DO, and colleagues of Hospital for Joint Disease, New York University, report that placing a topical Lidoderm patch provides an effective adjunct treatment in post-operative ...

The drug maker added an amendment to a citizen petition it filed with the FDA in 2006 concerning the drug Lidoderm (lidocaine), a patch used to treat post-herpetic neuralgia, a painful condition ...

Watson Pharma intends to begin shipments of its generic version of Lidoderm in September 2013 per the terms of its settlement agreement with Endo. Watson believes it is entitled to a 180-day period of ...

The US Department of Health and Human Services (HHS) has issued Endo Pharmaceuticals a subpoena regarding the promotion of its post-shingles pain patch Lidoderm. The subpoena requests documents from ...

Pharma has its latest pay-for-delay settlement. In a pair of deals with two plaintiff classes over generic Lidoderm delays, Endo, Teva and Japanese drugmaker Teikoku Seiyaku have agreed to fork over ...

For former Endo sales rep Peggy Ryan, the pivotal moment came about three years into her employment with the Malvern, PA-based company. She was at a national meeting, where the topic of discussion was ...

September 28, 2010 (Las Vegas, Nevada) — The use of a transdermal lidocaine 5% patch (Lidoderm, Endo Pharmaceuticals) benefits patients who have undergone unilateral knee replacement surgery by ...

Endo Pharmaceuticals was issued a subpoena by the Department of Health and Human Services regarding the promotion of its post-shingles pain patch Lidoderm, requesting documents from 1999 to the ...

Says partners got para IV notification from Watson Labs Says to defend Lidoderm's intellectual property rights Shares down 3 pct pre-market Jan 19 (Reuters) - Endo Pharmaceuticals Holdings Inc said ...

SAN FRANCISCO (MarketWatch) -- Endo Pharmaceuticals Holdings Inc. after Monday's closing bell said that net sales of Lidoderm, its largest-selling product, are expected to be below underlying demand ...